세계의 항체약물접합체(ADC) 시장 규모, 점유율, 동향 분석 : 용도별, 제품별, 페이로드별, 기술별, 유통경로별, 지역별, 부문별 예측(2025-2033년)

Antibody Drug Conjugates Market Summary

The global antibody drug conjugates market size was estimated at USD 12.26 billion in 2024 and is projected to reach USD 32.11 billion by 2033, growing at a CAGR of 10.49% from 2025 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for targeted therapies that offer greater efficacy with reduced systemic toxicity.

The antibody-drug conjugates (ADC) market is experiencing significant growth, driven by advancements in targeted therapies, increasing clinical trials, and strategic investments by pharmaceutical companies. Ongoing research and development activities support this expansion, with ongoing advancements in targeted therapy and precision medicine increasing the appeal of ADCs as a preferred treatment option in oncology. The rising global incidence of various cancer types has created a demand for therapies that offer high efficacy with fewer adverse effects. ADCs address this need by delivering potent cytotoxic agents directly to cancer cells while sparing healthy tissues, thereby improving patient outcomes. The increasing number of clinical trials and regulatory approvals reflects the commitment of pharmaceutical companies to invest in this novel treatment class.

For instance, in June 2025, the U.S. approved Datroway (datopotamab deruxtecan), an ADC targeting the TROP 2 protein, for the treatment of advanced non-small cell lung cancer in adults who had previously undergone treatment. Additionally, in February 2025, the FDA approved Datroway for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer in adults who had undergone prior endocrine-based therapy and chemotherapy. Similarly, in April 2025, GSK received UK regulatory approval for Blenrep, an ADC for the treatment of adults with multiple myeloma in combination with another medication after at least one prior therapy. These developments highlight the continued growth and validation of ADC therapies.

Global Antibody Drug Conjugates Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antibody drug conjugates market report based on application, product, payload, technology, distribution channel, and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Breast Cancer
• Blood Cancer
  • Lymphoma
  • Leukemia
• Urothelial Carcinoma
• Ovarian Cancer
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Kadcyla (ado-trastuzumab emtansine)
• Enhertu (trastuzumab deruxtecan)
• Trodelvy (sacituzumab govitecan)
• Adcetris (brentuximab vedotin)
• Polivy (polatuzumab vedotin)
• Others (Padcev, Tivdak, Elahere, Zynlonta, Mylotarg, Besponsa)
• Payload Outlook (Revenue, USD Million, 2021 - 2033)
• Auristatins (MMAE, MMAF)
• Maytansinoids (DM1, DM4)
• Calicheamicin Derivatives
• Topoisomerase I Inhibitors (SN-38, DXd)
• Pyrrolobenzodiazepine (PBD) Dimers
• Others
• TechnologyOutlook (Revenue, USD Million, 2021 - 2033)
• Cleavable Linker
• Non-Cleavable Linker
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacy
• Specialty Pharmacy
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Product
  • 1.2.3. Payload
  • 1.2.4. Technology
  • 1.2.5. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Antibody Drug Conjugates Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Antibody Drug Conjugates Market: Application Business Analysis

• 4.1. Application Market Share, 2024 & 2033
• 4.2. Application Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 4.4. Breast Cancer
  • 4.4.1. Breast Cancer Market, 2021 - 2033 (USD Million)
• 4.5. Blood Cancer
  • 4.5.1. Blood Cancer Market, 2021 - 2033 (USD Million)
• 4.6. Lymphoma
  • 4.6.1. Lymphoma Market, 2021 - 2033 (USD Million)
• 4.7. Leukemia
  • 4.7.1. Leukemia Market, 2021 - 2033 (USD Million)
• 4.8. Urothelial Carcinoma
  • 4.8.1. Urothelial Carcinoma Market, 2021 - 2033 (USD Million)
• 4.9. Ovarian Cancer
  • 4.9.1. Ovarian Cancer Market, 2021 - 2033 (USD Million)
• 4.10. Others
  • 4.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Antibody Drug Conjugates Market: Product Business Analysis

• 5.1. Product Market Share, 2024 & 2033
• 5.2. Product Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 5.4. Kadcyla
  • 5.4.1. Kadcyla Market, 2021 - 2033 (USD Million)
• 5.5. Enhertu
  • 5.5.1. Enhertu Market, 2021 - 2033 (USD Million)
• 5.6. Trodelvy
  • 5.6.1. Trodelvy Market, 2021 - 2033 (USD Million)
• 5.7. Adcetris
  • 5.7.1. Adcetris Market, 2021 - 2033 (USD Million)
• 5.8. Polivy
  • 5.8.1. Polivy Market, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Antibody Drug Conjugates Market: Payload Business Analysis

• 6.1. Payload Market Share, 2024 & 2033
• 6.2. Payload Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by payload, 2021 to 2033 (USD Million)
• 6.4. Auristatins
  • 6.4.1. Auristatins Market, 2021 - 2033 (USD Million)
• 6.5. Maytansinoids
  • 6.5.1. Maytansinoids Market, 2021 - 2033 (USD Million)
• 6.6. Calicheamicin Derivatives
  • 6.6.1. Calicheamicin Derivatives Market, 2021 - 2033 (USD Million)
• 6.7. Topoisomerase I Inhibitors
  • 6.7.1. Topoisomerase I Inhibitors Market, 2021 - 2033 (USD Million)
• 6.8. Pyrrolobenzodiazepine (PBD) Dimers
  • 6.8.1. Pyrrolobenzodiazepine (PBD) Dimers Market, 2021 - 2033 (USD Million)
• 6.9. Others
  • 6.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Antibody Drug Conjugates Market: Technology Business Analysis

• 7.1. Technology Market Share, 2024 & 2033
• 7.2. Technology Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by technology, 2021 to 2033 (USD Million)
• 7.4. Cleavable Linker
  • 7.4.1. Cleavable Linker Market, 2021 - 2033 (USD Million)
• 7.5. Non- cleavable Linker
  • 7.5.1. Non- cleavable Linker Market, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Antibody Drug Conjugates Market: Distribution Channel Business Analysis

• 8.1. Distribution Channel Market Share, 2024 & 2033
• 8.2. Distribution Channel Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
• 8.4. Hospital Pharmacy
  • 8.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
• 8.5. Specialty Pharmacy
  • 8.5.1. Specialty Pharmacy Market, 2021 - 2033 (USD Million)
• 8.6. Others
  • 8.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 9. Antibody Drug Conjugates Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2033
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 9.4. North America
  • 9.4.1. North America Antibody Drug Conjugates Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Reimbursement Framework
    • 9.4.2.5. U.S. Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Reimbursement Framework
    • 9.4.3.5. U.S. Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Reimbursement Framework
    • 9.4.4.5. Mexico Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Reimbursement Framework
    • 9.5.2.5. Uk Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Reimbursement Framework
    • 9.5.3.5. Germany Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Target Disease Prevalence
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. Reimbursement Framework
    • 9.5.4.5. France Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Target Disease Prevalence
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Reimbursement Framework
    • 9.5.5.5. Italy Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Target Disease Prevalence
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Reimbursement Framework
    • 9.5.6.5. Spain Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. Denmark
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Target Disease Prevalence
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. Reimbursement Framework
    • 9.5.7.5. Denmark Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.8. Sweden
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Target Disease Prevalence
    • 9.5.8.3. Regulatory Framework
    • 9.5.8.4. Reimbursement Framework
    • 9.5.8.5. Sweden Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.9. Norway
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Target Disease Prevalence
    • 9.5.9.3. Regulatory Framework
    • 9.5.9.4. Reimbursement Framework
    • 9.5.9.5. Norway Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Reimbursement Framework
    • 9.6.2.5. Japan Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Reimbursement Framework
    • 9.6.3.5. China Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Reimbursement Framework
    • 9.6.4.5. India Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.5. Australia
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Reimbursement Framework
    • 9.6.5.5. Australia Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.6. South Korea
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Target Disease Prevalence
    • 9.6.6.3. Regulatory Framework
    • 9.6.6.4. Reimbursement Framework
    • 9.6.6.5. South Korea Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Target Disease Prevalence
    • 9.6.7.3. Regulatory Framework
    • 9.6.7.4. Reimbursement Framework
    • 9.6.7.5. Thailand Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Target Disease Prevalence
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. Reimbursement Framework
    • 9.7.2.5. Japan Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Target Disease Prevalence
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Reimbursement Framework
    • 9.7.3.5. China Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.8. Middle East and Africa
  • 9.8.1. Middle East and Africa Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Target Disease Prevalence
    • 9.8.2.3. Regulatory Framework
    • 9.8.2.4. Reimbursement Framework
    • 9.8.2.5. South Africa Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Target Disease Prevalence
    • 9.8.3.3. Regulatory Framework
    • 9.8.3.4. Reimbursement Framework
    • 9.8.3.5. Saudi Arabia Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Target Disease Prevalence
    • 9.8.4.3. Regulatory Framework
    • 9.8.4.4. Reimbursement Framework
    • 9.8.4.5. UAE Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Target Disease Prevalence
    • 9.8.5.3. Regulatory Framework
    • 9.8.5.4. Reimbursement Framework
    • 9.8.5.5. Kuwait Antibody Drug Conjugates Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Seagen, Inc.
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Application Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. Takeda Pharmaceutical Company Ltd.
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Application Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. AstraZeneca
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Application Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. F. Hoffmann-La Roche Ltd.
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Application Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. Pfizer, Inc.
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Application Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Gilead Sciences, Inc.
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Application Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. Daiichi Sankyo Company Ltd.
    • 10.5.7.1. Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Application Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. antibody drug conjugates Therapeutics SA
    • 10.5.8.1. Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Application Benchmarking
    • 10.5.8.4. Strategic Initiatives